Chemoablation of metastatic melanoma with rose bengal (PV-10).

Agarwala, S. S.; Je, Thompson; Smithers, B. M.; Ross, M. I.; Coventry, Brendon J.; Minor, David R.; Scoggins, Charles R.; Wachter, E. A.

doi:10.1200/jco.2010.28.15_suppl.8534

Cited by 9 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 3x ROB substantially reduced the cell viability (34%). ROB has been tested to ablate certain types of cancer cells including melanoma [48], [49], and so it is not surprising that ROB is cytotoxic to SH-SY5Y cells.…”

Section: Resultsmentioning

confidence: 99%

Halogenation Generates Effective Modulators of Amyloid-Beta Aggregation and Neurotoxicity

2013

View full text Add to dashboard Cite

Halogenation of organic compounds plays diverse roles in biochemistry, including selective chemical modification of proteins and improved oral absorption/blood-brain barrier permeability of drug candidates. Moreover, halogenation of aromatic molecules greatly affects aromatic interaction-mediated self-assembly processes, including amyloid fibril formation. Perturbation of the aromatic interaction caused by halogenation of peptide building blocks is known to affect the morphology and other physical properties of the fibrillar structure. Consequently, in this article, we investigated the ability of halogenated ligands to modulate the self-assembly of amyloidogenic peptide/protein. As a model system, we chose amyloid-beta peptide (Aβ), which is implicated in Alzheimer’s disease, and a novel modulator of Aβ aggregation, erythrosine B (ERB). Considering that four halogen atoms are attached to the xanthene benzoate group in ERB, we hypothesized that halogenation of the xanthene benzoate plays a critical role in modulating Aβ aggregation and cytotoxicity. Therefore, we evaluated the modulating capacities of four ERB analogs containing different types and numbers of halogen atoms as well as fluorescein as a negative control. We found that fluorescein is not an effective modulator of Aβ aggregation and cytotoxicity. However, halogenation of either the xanthenes or benzoate ring of fluorescein substantially enhanced the inhibitory capacity on Aβ aggregation. Such Aβ aggregation inhibition by ERB analogs except rose bengal correlated well to the inhibition of Aβ cytotoxicity. To our knowledge, this is the first report demonstrating that halogenation of aromatic rings substantially enhance inhibitory capacities of small molecules on Aβ-associated neurotoxicity via Aβ aggregation modulation.

show abstract

Section: Resultsmentioning

confidence: 99%

Halogenation Generates Effective Modulators of Amyloid-Beta Aggregation and Neurotoxicity

2013

View full text Add to dashboard Cite

show abstract

“…Topical or intralesional immune modulators (diphencyprone, 20 PV10 21 ) have been described as a treatment modality for RCNM, but we felt that immune therapies were less likely to be effective in the rapidly growing disease we observed. Because of a paucity of data, it is not possible to definitively define their role in the treatment of RCNM as compared with HDR BT.…”

Section: Discussionmentioning

confidence: 92%

Treatment of regional cutaneous nodular metastases from melanoma using high‐dose rate mould brachytherapy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The next phase II trial revealed a 33% complete response rate, 28% partial response rate, 18% with stability of their disease, and an objective response rate of 49% in target lesions. 56 The locoregional control of disease (complete + partial + stable) was 71%. Additional analyses of those who exhibited complete response also demonstrated a considerably longer progression-free survival time (11.1 months) compared with those with progressive or even stable disease (2.7 and 2.8, respectively).…”

Section: Intralesional Therapiesmentioning

confidence: 95%

“…Additional analyses of those who exhibited complete response also demonstrated a considerably longer progression-free survival time (11.1 months) compared with those with progressive or even stable disease (2.7 and 2.8, respectively). 56 …”

Section: Intralesional Therapiesmentioning

confidence: 99%

Immunotherapy in the management of melanoma: current status

Alston¹,

Brewer²

2013

ITT

View full text Add to dashboard Cite

As the rate of melanoma continues to increase, so does the need for more effective and durable therapies. Despite considerable research, the management of advanced disease remains challenging. Numerous therapies are being investigated, many of which aim at upregulating the immune system’s innate ability to attack the tumor. Cytotoxic T lymphocyte antigen 4 antibodies are immune stimulants that act as negative regulators of the immune system by modifying an antitumor T-cell response. Ipilimumab, one such cytotoxic T lymphocyte antigen 4 antibody, and vemurafenib, a BRAF competitive inhibitor, were approved as first-line therapies in 2011 due to improved survival rates versus standard chemotherapy. Allovectin-7 is a lipid plasmid that encodes for major histone compatibility complex DNA sequences. It has led to increases in cytotoxic T-cell production, which subsequently attacks the tumor. OncoVEX, an oncolytic herpes virus, and PV-10, a chemoablative agent, have yielded promising results in metastatic lesions and have demonstrated a unique “bystander” phenomenon. In this paper we review the basics of melanoma from the pathophysiology, risk factors, signs, diagnostic approaches, and current status of immunologic management of melanoma.

show abstract

Chemoablation of metastatic melanoma with rose bengal (PV-10).

Cited by 9 publications

References 0 publications

Halogenation Generates Effective Modulators of Amyloid-Beta Aggregation and Neurotoxicity

Halogenation Generates Effective Modulators of Amyloid-Beta Aggregation and Neurotoxicity

Treatment of regional cutaneous nodular metastases from melanoma using high‐dose rate mould brachytherapy

Immunotherapy in the management of melanoma: current status

Contact Info

Product

Resources

About